Current management of limited-stage SCLC and CONVERT trial impact: results of the EORTC Lung Cancer Group survey
AffiliationDepartment of Radiation Oncology, Gustave Roussy, Institut d'Oncologie Thoracique (IOT), INSERM U1030 Molecular Radiotherapy, Universite Paris-Saclay, F-94805, Villejuif, France;
MetadataShow full item record
AbstractOBJECTIVES: The CONVERT trial showed that twice-daily (BD) concurrent chemoradiotherapy should continue to be considered the standard of care in localised LS-SCLC. A survey was conducted to assess the impact of the CONVERT trial in clinical practice and to identify any relevant research questions for future trials in this setting. METHODS AND MATERIALS: An EORTC Group online survey of LS-SCLC practice was distributed to the EORTC LCG and to members of several European thoracic oncology societies between April and December 2018. RESULTS: 198 responses were analysed. The majority of respondents (88%, n?=?174) were aware of the CONVERT trial. Radiation oncologists comprised 56% of all respondents. Once-daily (OD) radiotherapy is still the most commonly used regimen, however the use of concurrent BD radiotherapy increased after the publication of CONVERT (n?=?59/186, 32% prior to and n?=?78/187, 42% after the publication, p?=?0.053). The main reasons for not implementing BD after the CONVERT publication were logistical issues (n?=?88, 44%), inconvenience for patients (n?=?56, 28%), and the absence of a statistical survival difference between the two arms in CONVERT (n?=?38, 19%). Brain MRI was used by 28% during staging but more than half (60%) of the respondents did not routinely image the brain during follow-up. The main research questions of interest in LS-SCLC were 1) integrating novel targeted therapies-immunotherapies (n?=?160, 81%), 2) PCI (+/- hippocampal sparing) vs. MRI surveillance (n?=?140, 71%) and, 3) biomarker driven trials (n?=?92, 46%). CONCLUSION: Once daily radiotherapy (60-66?Gy in 30-33 fractions) remains the most prescribed radiotherapy fractionation, despite the findings suggested by the CONVERT trial.
CitationLevy A, Hendriks LEL, Le Pechoux C, Falk S, Besse B, Novello S, et al. Current management of limited-stage SCLC and CONVERT trial impact: results of the EORTC Lung Cancer Group survey. Lung Cancer. 2019 Oct;136:145-7.
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.
- Authors: Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S, Le Pechoux C, McMenemin R, Mohammed N, O'Brien M, Pantarotto J, Surmont V, Van Meerbeeck JP, Woll PJ, Lorigan P, Blackhall F, CONVERT Study Team.
- Issue date: 2017 Aug
- Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status.
- Authors: Faivre-Finn C, Falk S, Ashcroft L, Bewley M, Lorigan P, Wilson E, Groom N, Snee M, Fournel P, Cardenal F, Bezjak A, Blackhall F
- Issue date: 2016 Jan 20
- Radiation therapy in small cell lung cancer: a national Italian survey.
- Authors: Ciammella P, Timon G, Bruni A, Franceschini D, Borghetti P, Giaj-Levra N, Greco C, Scotti V, Trovo M, On the behalf of Associazione Italiana Radioterapia Oncologica (AIRO).
- Issue date: 2018 Jul
- Prophylactic Cranial Irradiation for Limited-Stage Small-Cell Lung Cancer: Survey of US Radiation Oncologists on Current Practice Patterns.
- Authors: Farrell MJ, Yahya JB, Degnin C, Chen Y, Holland JM, Henderson MA, Jaboin JJ, Harkenrider MM, Thomas CR Jr, Mitin T
- Issue date: 2018 Jul
- Association of Chemoradiotherapy With Outcomes Among Patients With Stage I to II vs Stage III Small Cell Lung Cancer: Secondary Analysis of a Randomized Clinical Trial.
- Authors: Salem A, Mistry H, Hatton M, Locke I, Monnet I, Blackhall F, Faivre-Finn C
- Issue date: 2019 Mar 1